Dendritic cell maturation, but not type I interferon exposure, restricts infection by HTLV-1, and viral transmission to T-cells

PLoS Pathog. 2017 Apr 20;13(4):e1006353. doi: 10.1371/journal.ppat.1006353. eCollection 2017 Apr.

Abstract

Human T lymphotropic Virus type 1 (HTLV-1) is the etiological agent of Adult T cell Leukemia/Lymphoma (ATLL) and HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Both CD4+ T-cells and dendritic cells (DCs) infected with HTLV-1 are found in peripheral blood from HTLV-1 carriers. We previously demonstrated that monocyte-derived IL-4 DCs are more susceptible to HTLV-1 infection than autologous primary T-cells, suggesting that DC infection precedes T-cell infection. However, during blood transmission, breast-feeding or sexual transmission, HTLV-1 may encounter different DC subsets present in the blood, the intestinal or genital mucosa respectively. These different contacts may impact HTLV-1 ability to infect DCs and its subsequent transfer to T-cells. Using in vitro monocyte-derived IL-4 DCs, TGF-β DCs and IFN-α DCs that mimic DCs contacting HTLV-1 in vivo, we show here that despite their increased ability to capture HTLV-1 virions, IFN-α DCs restrict HTLV-1 productive infection. Surprisingly, we then demonstrate that it is not due to the antiviral activity of type-I interferon produced by IFN-α DCs, but that it is likely to be linked to a distinct trafficking route of HTLV-1 in IL-4 DCs vs. IFN-α DCs. Finally, we demonstrate that, in contrast to IL-4 DCs, IFN-α DCs are impaired in their capacity to transfer HTLV-1 to CD4 T-cells, both after viral capture and trans-infection and after their productive infection. In conclusion, the nature of the DCs encountered by HTLV-1 upon primo-infection and the viral trafficking route through the vesicular pathway of these cells determine the efficiency of viral transmission to T-cells, which may condition the fate of infection.

MeSH terms

  • Adult
  • Antiviral Agents / pharmacology*
  • Cytokines / immunology*
  • Dendritic Cells / immunology*
  • Dendritic Cells / virology
  • HTLV-I Infections / immunology*
  • HTLV-I Infections / transmission
  • HTLV-I Infections / virology
  • Human T-lymphotropic virus 1 / immunology*
  • Human T-lymphotropic virus 1 / pathogenicity
  • Human T-lymphotropic virus 1 / physiology
  • Humans
  • Interferon Type I / immunology
  • Models, Biological
  • Paraparesis, Tropical Spastic / immunology*
  • Paraparesis, Tropical Spastic / pathology
  • Paraparesis, Tropical Spastic / virology
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology

Substances

  • Antiviral Agents
  • Cytokines
  • Interferon Type I

Grants and funding

This work was supported by the “Ligue Nationale contre le Cancer, équipe labélisée program” EL2013-3 Mahieux to HD, RM and CJ. GR is funded by a joint funding program from the Lebanese National Council for Scientific Research CNRS-L and the Université Saint-Joseph USJ (Lebanon) and by a PhD grant from Fondation Merieux (France). HD and SA are funded by INSERM, CJ and RM are funded by the ENS de Lyon. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.